Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Management to Host Conference Call to Review Financial Results and Provide Corporate Update at 4:30PM Today MINNEAPOLIS , May 15, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized
View HTML
Toggle Summary Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019
Conference Call to be held May 15, 2019 , at 4:30pm Eastern Time MINNEAPOLIS , May 13, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces that it will report First Quarter 2019 financial results for the period ended March 31, 2019 ,
View HTML
Toggle Summary Precision Therapeutics’ Subsidiary Helomics and National Alopecia Areata Foundation Sign Services Agreement to Provide Next-Generation Patient Registry for Alopecia Areata Research
MINNEAPOLIS and SAN RAFAEL, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a services agreement between its wholly owned subsidiary, Helomics and the National Alopecia Areata Foundation (NAAF), which serves the
View HTML
Toggle Summary Precision Therapeutics’ Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments
Collaboration Receives $300,000 CAD Grant to Further Develop and Commercialize TumorGenesis Oncology Discovery Technologies MINNEAPOLIS , April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly owned subsidiary,
View HTML
Toggle Summary Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine Opportunities for Cancer Patients
Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform to SpeciCare for their PIONEER Initiative functional precision medicine trial PITTSBURGH , April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today
View HTML
Toggle Summary Precision Therapeutics’ Subsidiary Helomics to Collaborate with Viome to Explore the Impact of the Gut Microbiome on Ovarian Cancer
MINNEAPOLIS , April 09, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a collaboration between its wholly owned subsidiary, Helomics, and Viome, a new kind of healthcare company transforming health at the molecular level, to study
View HTML
Toggle Summary Precision Therapeutics Announces Completion of Merger with Helomics Holding Corporation
MINNEAPOLIS , April 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision Therapeutics” or “the Company”), today announced the completion of its merger with Helomics Holding Corporation (“Helomics”), which has become the Company’s wholly owned subsidiary, providing
View HTML
Toggle Summary Precision Therapeutics Reports Year End 2018 Financial Results and Provides Corporate Update
MINNEAPOLIS , April 01, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to Women’s Oncology, announced today financial results for the quarter and fiscal year ended December 31, 2018 and
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Pricing of Public Offering of Up to $1.2 Million of Units
MINNEAPOLIS , March 27, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced the pricing of its previously announced public offering of its common stock and warrants to purchase common stock, with anticipated gross proceeds of up to
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
MINNEAPOLIS , March 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be
View HTML